89Zr as a promising radionuclide and it’s applications for effective cancer imaging

Sarcan, Elif Tugce; Silindir-Gunay, Mine; Özer, A. Yekta; Hartman, Neil R.

doi:10.1007/s10967-021-07928-0

Cited by 12 publications

(5 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most importantly, the radiotracer should have a long-lived physical half-life (Mohammadpour-Ghazi et al 2023 ). Zirconium-89 (t ½ = 78 h), a positron emitting radionuclide of relatively low energy, is produced via the proton bombardment of naturally abundant yttrium-89 using a biomedical cyclotron (Sarcan et al 2021 ; Mohammadpour-Ghazi et al 2023 ; Gordon and Vivian 1984 ) and its production is characterized by high purity and high specific activity (Sarcan et al 2021 ; Holland et al 2009 ; Ikotun and Lapi 2011 ). In the current study, we described a method for efficient and rapid labelling of leukocytes with a PET-emitting, long-lived radioisotope, i.e., 89 Zr.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations

Kahts,

Guo,

Kommidi

et al. 2023

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background The non-invasive imaging of leukocyte trafficking to assess inflammatory areas and monitor immunotherapy is currently generating great interest. There is a need to develop more robust cell labelling and imaging approaches to track living cells. Positron emission tomography (PET), a highly sensitive molecular imaging technique, allows precise signals to be produced from radiolabelled moieties. Here, we developed a novel leukocyte labelling approach with the PET radioisotope zirconium-89 (89Zr, half-life of 78.4 h). Experiments were carried out using human leukocytes, freshly isolated from whole human blood. Results The 89Zr-leukocyte labelling efficiency ranged from 46 to 87% after 30–60 min. Radioactivity concentrations of labelled cells were up to 0.28 MBq/1 million cells. Systemically administered 89Zr-labelled leukocytes produced high-contrast murine PET images at 1 h–5 days post injection. Murine biodistribution data showed that cells primarily distributed to the lung, liver, and spleen at 1 h post injection, and are then gradually trafficked to liver and spleen over 5 days. Histological analysis demonstrated that exogenously 89Zr-labelled human leukocytes were present in the lung, liver, and spleen at 1 h post injection. However, intravenously injected free [89Zr]Zr4+ ion showed retention only in the bone with no radioactivity in the lung at 5 days post injection, which implied good stability of radiolabelled leukocytes in vivo. Conclusions Our study presents a stable and generic radiolabelling technique to track leukocytes with PET imaging and shows great potential for further applications in inflammatory cell and other types of cell trafficking studies.

show abstract

Section: Discussionmentioning

confidence: 99%

“…89 Zr can be obtained with high radionuclide purity and at high yields. 89 Zr benefits from its relatively low mean positron emission energy of 395.5 keV, which translates into high image resolution (Fairclough et al 2016 ; Deri et al 2013 ; Sarcan et al 2021 ).…”

Section: Introductionmentioning

confidence: 99%

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations

Kahts,

Guo,

Kommidi

et al. 2023

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…They seeded labeled cell suspensions into 6-well plates and scanned them (PET/CT and PET/MRI), using a specific activity of 27.8 kBq/10 6 cells. Results using this in vitro model showed that 6.8×10 4 was the minimal number of labeled cells needed to obtain PET imaging. shows the schematic representation of extracellular labeling with 89 Zr-deferoxamine-NCS that binds to protein lysine on the cell membrane.…”

Section: Labeling Of Non-genetic Engineering Cellsmentioning

confidence: 94%

Zirconium immune-complexes for PET molecular imaging: Current status and prospects

Meléndez‐Alafort

Ferro‐Flores

Nardo³

et al. 2023

Coordination Chemistry Reviews

View full text Add to dashboard Cite

“…After the annihilation of the positron and electron, 2 gamma rays with 511 keV energy are launched. PET imaging methods show better sensitivity, specificity, and higher resolution than SPECT imaging methods (Kaur et al, 2012;Sarcan, Silindir-Gunay, Ozer, & Hartman, 2021). F-18, N-13, O-15, and C-11 are conventional PET radionuclides with short half-lives.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal Antibodies and Immuno-PET Imaging: An Overview

Sarcan

Özer

2023

Fabad J Pharm Sci

View full text Add to dashboard Cite

Radiopharmaceuticals are radioactive medicines used for imaging and/or therapeutic purposes, consisting of radionuclidic and pharmaceutical parts. While PET and SPECT methods are used for imaging purposes, immuno-PET imaging method has gained popularity, recently. Immuno-PET imaging method, is a combination of PET radionuclides and biomolecules, especially monoclonal antibodies (mAb), proteins, peptides, are frequently used for the imaging of different types of cancer. Radionuclides with long half-lives are generally used in immuno-PET imaging. Long biological half-lives of mAbs is the most important reason to be preferred for immuno-PET imaging. Today, Zirconium-89 (Zr-89), Iodine-124 (I-124) with long half-lives and Copper-64 (Cu-64) and Yttrium-86 (Y-86) radionuclides with relatively long half-lives are preferred in immuno-PET imaging. In this article, studies on Zr-89, Cu-64, I-124 and Y-86-labeled mAbs with long half-life and clinical and preclinical studies were reviewed. Also, comparison of these 4 radionuclides, which are frequently used in the labelling of biomolecules (particularly mAbs) with is included.

show abstract

89Zr as a promising radionuclide and it’s applications for effective cancer imaging

Cited by 12 publications

References 107 publications

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations

Zirconium immune-complexes for PET molecular imaging: Current status and prospects

Monoclonal Antibodies and Immuno-PET Imaging: An Overview

Contact Info

Product

Resources

About